Replies to post #14914 on RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

I've made this point as well, but I think that in the context of RD, it's a bit beside the point. As studies go, this is about as small and simple as it gets, and a positive result would increase COR's valuation. So wrt the RD trial, I think it makes sense to go ahead and do it.

The eventual conflict between management's interests and our interests will more likely kick in after the RD trial. If the result is negative, I don't think buyout offers would be particularly attractive to anyone, so it could be that we're all swinging for the fences together. In the event of a positive outcome, there are all kinds of stupid things that can be done, but anyone looking for an exit at ~$1.50 should be able to get out in that price range.

[tonyvanw]

<So even if a BP offered $1.00-1.50, which would represent a nice double/triple for current shareholders, Cortex management won't be very interested. So in that respect, management's interests right now are diametrically opposed to those of regular shareholders. >

gfp - I disagree with your conclusion. You are making the assumption that $1.00 - 1/50 would be attractive to current shareholders. Frankly, if management tomorrow announced the sale of the company for a price in that range, I would not be a happy camper.

Depending on results over the course of this year, I may change my mind, but that would be on the basis of new information, not what I know now.